Report of an international working group to standardize response criteria for myelodysplastic syndromes

B. D. Cheson, J. M. Bennett, H. Kantarjian, A. Pinto, C. A. Schiffer, Stephen D Nimer, B. Lowenberg, M. Beran, T. M. De Witte, R. M. Stone, M. Mittelman, G. F. Sanz, P. W. Wijermans, S. Gore, P. L. Greenberg

Research output: Contribution to journalArticle

584 Citations (Scopus)

Abstract

Standardized criteria for assessing response are essential to ensure comparability among clinical trials for patients with myelodysplastic syndromes (MDS). An international working group of experienced clinicians involved in the management of patients with MDS reviewed currently used response definitions and developed a uniform set of guidelines for future clinical trials in MDS. The MDS differ from many other hematologic malignancies in their chronicity and the morbidity and mortality caused by chronic cytopenias, often without disease progression to acute myeloid leukemia. Whereas response rates may be an important endpoint for phase 2 studies of new agents and may assist regulatory agencies in their evaluation and approval processes, an important goal of clinical trials in MDS should be to prolong patient survival. Therefore, these response criteria reflected 2 sets of goals in MDS: altering the natural history of the disease and alleviating disease-related complications with improved quality of life. It is anticipated that the recommendations presented will require modification as more is learned about the molecular biology and genetics of these disorders. Until then, it is hoped these guidelines will serve to improve communication among investigators and to ensure comparability among clinical trials. (C) 2000 by The American Society of Hematology.

Original languageEnglish
Pages (from-to)3671-3674
Number of pages4
JournalBlood
Volume96
Issue number12
StatePublished - Dec 1 2000
Externally publishedYes

Fingerprint

Myelodysplastic Syndromes
Clinical Trials
Molecular biology
Molecular Biology
Guidelines
Inborn Genetic Diseases
Communication
Hematologic Neoplasms
Acute Myeloid Leukemia
Disease Progression
Quality of Life
Research Personnel
Morbidity
Survival
Mortality

ASJC Scopus subject areas

  • Hematology

Cite this

Cheson, B. D., Bennett, J. M., Kantarjian, H., Pinto, A., Schiffer, C. A., Nimer, S. D., ... Greenberg, P. L. (2000). Report of an international working group to standardize response criteria for myelodysplastic syndromes. Blood, 96(12), 3671-3674.

Report of an international working group to standardize response criteria for myelodysplastic syndromes. / Cheson, B. D.; Bennett, J. M.; Kantarjian, H.; Pinto, A.; Schiffer, C. A.; Nimer, Stephen D; Lowenberg, B.; Beran, M.; De Witte, T. M.; Stone, R. M.; Mittelman, M.; Sanz, G. F.; Wijermans, P. W.; Gore, S.; Greenberg, P. L.

In: Blood, Vol. 96, No. 12, 01.12.2000, p. 3671-3674.

Research output: Contribution to journalArticle

Cheson, BD, Bennett, JM, Kantarjian, H, Pinto, A, Schiffer, CA, Nimer, SD, Lowenberg, B, Beran, M, De Witte, TM, Stone, RM, Mittelman, M, Sanz, GF, Wijermans, PW, Gore, S & Greenberg, PL 2000, 'Report of an international working group to standardize response criteria for myelodysplastic syndromes', Blood, vol. 96, no. 12, pp. 3671-3674.
Cheson BD, Bennett JM, Kantarjian H, Pinto A, Schiffer CA, Nimer SD et al. Report of an international working group to standardize response criteria for myelodysplastic syndromes. Blood. 2000 Dec 1;96(12):3671-3674.
Cheson, B. D. ; Bennett, J. M. ; Kantarjian, H. ; Pinto, A. ; Schiffer, C. A. ; Nimer, Stephen D ; Lowenberg, B. ; Beran, M. ; De Witte, T. M. ; Stone, R. M. ; Mittelman, M. ; Sanz, G. F. ; Wijermans, P. W. ; Gore, S. ; Greenberg, P. L. / Report of an international working group to standardize response criteria for myelodysplastic syndromes. In: Blood. 2000 ; Vol. 96, No. 12. pp. 3671-3674.
@article{326d74e01ef34134b1e622e5d5dbcfb2,
title = "Report of an international working group to standardize response criteria for myelodysplastic syndromes",
abstract = "Standardized criteria for assessing response are essential to ensure comparability among clinical trials for patients with myelodysplastic syndromes (MDS). An international working group of experienced clinicians involved in the management of patients with MDS reviewed currently used response definitions and developed a uniform set of guidelines for future clinical trials in MDS. The MDS differ from many other hematologic malignancies in their chronicity and the morbidity and mortality caused by chronic cytopenias, often without disease progression to acute myeloid leukemia. Whereas response rates may be an important endpoint for phase 2 studies of new agents and may assist regulatory agencies in their evaluation and approval processes, an important goal of clinical trials in MDS should be to prolong patient survival. Therefore, these response criteria reflected 2 sets of goals in MDS: altering the natural history of the disease and alleviating disease-related complications with improved quality of life. It is anticipated that the recommendations presented will require modification as more is learned about the molecular biology and genetics of these disorders. Until then, it is hoped these guidelines will serve to improve communication among investigators and to ensure comparability among clinical trials. (C) 2000 by The American Society of Hematology.",
author = "Cheson, {B. D.} and Bennett, {J. M.} and H. Kantarjian and A. Pinto and Schiffer, {C. A.} and Nimer, {Stephen D} and B. Lowenberg and M. Beran and {De Witte}, {T. M.} and Stone, {R. M.} and M. Mittelman and Sanz, {G. F.} and Wijermans, {P. W.} and S. Gore and Greenberg, {P. L.}",
year = "2000",
month = "12",
day = "1",
language = "English",
volume = "96",
pages = "3671--3674",
journal = "Blood",
issn = "0006-4971",
publisher = "American Society of Hematology",
number = "12",

}

TY - JOUR

T1 - Report of an international working group to standardize response criteria for myelodysplastic syndromes

AU - Cheson, B. D.

AU - Bennett, J. M.

AU - Kantarjian, H.

AU - Pinto, A.

AU - Schiffer, C. A.

AU - Nimer, Stephen D

AU - Lowenberg, B.

AU - Beran, M.

AU - De Witte, T. M.

AU - Stone, R. M.

AU - Mittelman, M.

AU - Sanz, G. F.

AU - Wijermans, P. W.

AU - Gore, S.

AU - Greenberg, P. L.

PY - 2000/12/1

Y1 - 2000/12/1

N2 - Standardized criteria for assessing response are essential to ensure comparability among clinical trials for patients with myelodysplastic syndromes (MDS). An international working group of experienced clinicians involved in the management of patients with MDS reviewed currently used response definitions and developed a uniform set of guidelines for future clinical trials in MDS. The MDS differ from many other hematologic malignancies in their chronicity and the morbidity and mortality caused by chronic cytopenias, often without disease progression to acute myeloid leukemia. Whereas response rates may be an important endpoint for phase 2 studies of new agents and may assist regulatory agencies in their evaluation and approval processes, an important goal of clinical trials in MDS should be to prolong patient survival. Therefore, these response criteria reflected 2 sets of goals in MDS: altering the natural history of the disease and alleviating disease-related complications with improved quality of life. It is anticipated that the recommendations presented will require modification as more is learned about the molecular biology and genetics of these disorders. Until then, it is hoped these guidelines will serve to improve communication among investigators and to ensure comparability among clinical trials. (C) 2000 by The American Society of Hematology.

AB - Standardized criteria for assessing response are essential to ensure comparability among clinical trials for patients with myelodysplastic syndromes (MDS). An international working group of experienced clinicians involved in the management of patients with MDS reviewed currently used response definitions and developed a uniform set of guidelines for future clinical trials in MDS. The MDS differ from many other hematologic malignancies in their chronicity and the morbidity and mortality caused by chronic cytopenias, often without disease progression to acute myeloid leukemia. Whereas response rates may be an important endpoint for phase 2 studies of new agents and may assist regulatory agencies in their evaluation and approval processes, an important goal of clinical trials in MDS should be to prolong patient survival. Therefore, these response criteria reflected 2 sets of goals in MDS: altering the natural history of the disease and alleviating disease-related complications with improved quality of life. It is anticipated that the recommendations presented will require modification as more is learned about the molecular biology and genetics of these disorders. Until then, it is hoped these guidelines will serve to improve communication among investigators and to ensure comparability among clinical trials. (C) 2000 by The American Society of Hematology.

UR - http://www.scopus.com/inward/record.url?scp=0034554786&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0034554786&partnerID=8YFLogxK

M3 - Article

C2 - 11090046

AN - SCOPUS:0034554786

VL - 96

SP - 3671

EP - 3674

JO - Blood

JF - Blood

SN - 0006-4971

IS - 12

ER -